Tarsus Pharmaceuticals (TARS) Projected to Post Quarterly Earnings on Tuesday

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $58.80 million for the quarter.

Tarsus Pharmaceuticals Stock Down 1.8 %

Shares of TARS stock traded down $0.88 during trading hours on Friday, hitting $47.84. 465,364 shares of the company's stock traded hands, compared to its average volume of 608,831. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The stock's fifty day simple moving average is $51.87 and its two-hundred day simple moving average is $42.47. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -12.56 and a beta of 1.01.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Barclays lifted their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a research note on Monday, January 27th. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, November 15th. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Finally, Guggenheim reaffirmed a "buy" rating on shares of Tarsus Pharmaceuticals in a report on Monday, February 10th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.